InfanDx


InfanDx AG aims to contribute to this goal by developing a new generation of diagnostic tests for the care of neonates. Primary focus is the early identification of newborns suffering from critical oxygen supply deficit during birth (Asphyxia), a major cause for brain injury often followed by life long disabilitation. Nowadays, treatment that reduces morbidity is available. Unfortunately, it requires very early application after birth. Currently no test system is available that meets this crucial demand. InfanDx closes this diagnostic gap by carrying such test system through clinical development until it is available for routine use in the hospital.

Industries

health-care
health-diagnostics

Nr. of Employees

small (1-50)

InfanDx

Cologne, Nordrhein-Westfalen, Germany, Europe


Patents

Method of diagnosing and treating asphyxia

US-11313866-B2

View Details

Products

HypoxE® Test

A diagnostic test under development aimed at early detection of Hypoxic-Ischemic Encephalopathy (HIE) in newborns.

CompanionDx Hypothermia Test

A diagnostic test under development intended to support therapeutic decisions for hypothermia treatment in neonates with HIE.

clinical Decision Support System

A system under development designed to assist clinicians in making informed decisions regarding neonatal care based on diagnostic data.


Similar organizations

Browse all ORGANIZATIONS

JOIN OUR MAILING LIST

Stay Connected with MTEC

Keep up with active and upcoming solicitations, MTEC news and other valuable information.